Cooks Who Feed celebrity partners offer holiday recipes to make the day even more special
TORONTO, Canada – (November 2, 2021) – While many people have family favorite holiday recipes that they turn to each year, there are others who want to try something new. Whether they are adding it to their traditional dishes or creating a new holiday dining experience, it’s something people can have fun with. Having tried-and-true family recipes that are easy and pleasing is the key to pulling it off.
“This is the time of the year when people have holiday meal gatherings and spend more time dining with others,” explains Seema Sanghavi, founder of Cooks Who Feed. “Being able to try new recipes is always exciting and something for everyone to look forward to.”
To help make this holiday dining experience tastier, the celebrity chefs who have partnered with Cooks Who Feed are offering one of their favorite family holiday recipes. This gives people a chance to consider some new items, but they can trust in the fact that they are recipes that will turn out great and leave people wanting seconds.
The celebrity chef holiday recipes that people won’t want to miss this season include:
Art Smith. The executive chef and co-owner of several restaurants who coordinates and cooks for special events all around the world. Chef Art shares his recipe for Hummingbird Cake, which is one of Oprah’s favorites and is sold at his Disney Springs restaurant.
Christine Cushing. An award-winning chef with TV shows broadcast around the globe, and a line of tomato sauces in Ontario, Canada. Chef Christine shares her family’s recipe for a Greek version of lasagna.
Devan Rajkumar. Having honed his skills under celebrated chefs, he also provides high-end catering, and he became a regular guest on Canada’s hit show “Cityline.”Chef Devan shares his favorite recipe for chai-spiced holiday eggnog.
Chef Romain Avril. Best known for his appearances as a judge on “Top Chef Canada All-Stars,”he’s a Michelin-rated chef who is a frequent guest chef on television shows. Chef Romainshares a recipe for his favorite way to use up leftover turkey, which will help reduce food waste.
Seema Sanghavi. Founder the Cooks Who Feed nonprofit organization, she also has a passion for cooking and great food. She shares her favorite recipe for traditional chicken curry, which is sure to please.
“Dining is something that brings people together and creates lasting memories,” added Sanghavi. “When you have great dishes, you are bound to help make those meals even better. We hope people will find at least one recipe they would like to try this season.”
Cooks Who Feed is an organization on a mission to help feed those in need around the world. The organization has teamed up with celebrity chefs to design aprons for adults and kids. For each apron sold, 100 meals are provided to those in need. Thus far, the nonprofit has provided over 300,000 meals to hungry people around the world. They have a goal of reaching 500,000 meals by the end of 2021.
Each of the aprons offered are environmentally friendly, handmade through fair trade practices, and are sustainable. The apron for kids matches those made for adults. Every time an apron is sold, food waste is rescued and 100 meals are provided to those in need. The company does this by sharing its profits with its charity partners around the globe that rescue surplus food to reduce food waste and provide hunger relief.
Cooks Who Feed has launched a new part of their line of aprons, which are ones for kids. The new aprons come in three color combinations and two sizes, fitting ages 3-12. They are 100% 9oz cotton canvas, available in one size that fits ages 3-7 and one for ages 8-12. The aprons feature an adjustable neck strap, reinforced stress points, one double pocket below the waist, and a chest pocket. To see the aprons for children, visit the site:https://cookswhofeed.com/collections/child-aprons .
The company offers individual sales online, a retail line, and wholesale/corporate gifting options. The aprons are produced ethically in Dehli, India, where 40 women are employed to make them by hand. To get more information or help support the mission, visit the site at: https://cookswhofeed.com.
About Cooks Who Feed
Cooks Who Feed was founded by Seema Sanghavi, who has an advanced degree in marketing and strategic management, and over 12 years of experience in online marketing and product management. She has lived in several countries around the world and is an amateur chef. The company works with charity partners in India, Canada, and the U.S. to rescue food and serve it to those in need. To get more information, visit the site at: https://cookswhofeed.com.
Edward & Sons’ Let’s Do Organic® Brand Introduces Vegan & Gluten-Free Organic Sweet Potato Flour & Cassava Flour To Offer Chefs & Bakers Delectably Versatile Alternatives To Traditional Grain Flour
Growing Family Of Let’s Do Organic® Flour Products Also Includes Coconut Flour, Green Banana Flour & Chickpea Flour
CARPINTERIA, CA – Edward & Sons Trading Company™ (edwardandsons.com), a pioneer in the plant-based foods industry that first introduced Miso-Cup® instant soup and gluten-free Brown Rice Snaps® to American consumers in the 1970s, welcomes two new additions to the growing family of deliciously versatile grain-free flour products manufactured under the company’s Let’s Do Organic® brand: Organic Sweet Potato Flour and Organic Cassava Flour.
Offering consumers delectably authentic alternatives to grain and wheat flour, Organic Sweet Potato Flour and Organic Cassava Flour are tailor-made for those following a restricted diet or are simply anxious to explore healthier but equally flavorful flour options for cooking and baking.
Organic Sweet Potato Flour and Organic Cassava Flour join three other popular, grain-free flours already sold under the Let’s Do Organic® banner: Organic Coconut Flour, Organic Chickpea Flour and Organic Green Banana Flour.
Flour Power!
Providing the indulgent flavor and dense nutrition profile of sweet potatoes in a single multi-purpose grain-free flour, Let’s Do Organic®Sweet Potato Flour enables seasoned chefs and amateur home cooks alike to readily add rich layers of subtle sweetness to their favorite foods and desserts. As versatile as it is delicious, Let’s Do Organic® Sweet Potato Flour not only perfectly holds moisture when replacing or enhancing other flours during the preparation of cookies, muffins, breads and cakes, but is an excellent thickener for soups, sauces and gravies as well.
Let’s Do Organic® Sweet Potato Flour is USDA Organic; gluten-free, vegan and Kosher certified. The complete list of ingredients includes…Organic Sweet Potato – that’s it!
Let's Do Organic® Cassava Flour is a whole food, grain-free flour made from organic cassava roots (also known as manioc or yuca). Native to South America, cassava is a staple of tropical diets throughout the world thanks to the plant’s drought tolerance and carbohydrate content.
To enhance quality, edibility and nutritional integrity, Let’s Do Organic® experts wash, peel and slice whole cassava roots before drying them slowly and then milling them into a fine, gluten-free flour ideally suited to a diverse array of special diets and recipes. Baking with Let’s Do Organic® Cassava Flour is incredibly easy since it performs very much like wheat flour in the kitchen. For example, when a recipe calls for 1 cup of wheat flour, home chefs and bakers can simply replace it with 1 cup of Cassava Flour, with no extra eggs or liquid ingredients required.
What’s more, Let’s Do Organic® Cassava Flour adds a delightfully tempting smooth texture and subtle flavor to breads and pastries, is an excellent binder when baking cakes and cookies, and also serves as an effective thickener for gravies and sauces.
Like Sweet Potato Flour, Let’s Do Organic® Cassava Flour is USDA Organic; gluten-free, vegan and Kosher certified. Ingredients: just Organic Cassava Flour!
Available online at https://store.edwardandsons.com/collections/new-products and soon in health food stores and mainstream supermarkets nationwide, Let’s Do Organic® Sweet Potato Flour is offered in 12-ounce packages and Cassava Flour is sold in 14-ounce packages. Both have a MSRP of $5.99.
To check out the full line of Let’s Do Organic® flour products, as well as such other brand favorites as coconut flakes, shredded coconut, coconut milk, tapioca starch and organic ice cream cones, please visit https://store.edwardandsons.com/collections/lets-do-organic.
Commenting on the debut of the two new Let’s Do Organic® flour varieties, Edward & Sons’ founder and CEO Joel Dee said, “With so many home cooks yearning to explore healthier and more adventurous recipes during these challenging stay-at-home times, and trending diets avoiding gluten and grains, demand has never been greater for innovative alternatives to grain flour. Given the enthusiastic response we received after introducing all three previous Let’s Do Organic® flour products, we feel confident that our new Sweet Potato Flour and Cassava Flour will be welcome additions to countless kitchen pantries for many years to come.”
Edward & Sons Trading Company™ brands include Edward & Sons™, Let’s Do Gluten Free®, Let’s Do Organic®, the brand new Ecuadora™ line of Ecuadorian hearts of palm products, More Than Fair®, Native Forest®, Nature Factor®, Road’s End Organics® and organic gluten free specialty sauces under the Premier Japan® and The Wizard's® brands. Please visit www.edwardandsons.com for more information and recipes.
The Association of Faculties of Medicine of Canada levels the playing field and launches CANPREPP, an online portal where medical students can discover Canadian residency programs
OTTAWA, ON, Nov. 2, 2021 /CNW/ - Building on the success of last year, the Association of Faculties of Medicine of Canada (AFMC) launches the new and improved version of Canada's Portal for Residency Program Promotion (CANPREPP), an online portal where medical students can discover and experience medical residency programs across Canada.
Funded by the CMA Foundation, CANPREPP levels the playing field and gives students the ability, in one place, to access every program, along with providing every medical residency program with the opportunity to connect directly with students. With the unfortunate circumstances of COVID-19, students and academic medicine institutions were forced to cancel visiting electives. Face-to-face interaction was a huge loss for both learners and programs alike.
"When students were allowed to travel (to complete an elective) they were better able to see what the program and city were like because they had lived there for several weeks and had interacted with many different physicians in the program. That experience has been lost," explained Dr. Bernard Ho, an emergency medicine resident in Vancouver.
Selecting a residency program is challenging and a significant step in becoming a practicing physician. CANPREPP is the solution that came out of a virtual design sprint hosted early in 2020 to develop a tool for students and residency programs to connect virtually. The sprint team included medical students, residents, program directors and medical school deans from several organizations, including AFMC, the CMA Foundation, and the Canadian Medical Association.
"The AFMC is grateful for funding for the portal from the CMA Foundation and for the support of our partners. By working together, we have been able to deliver a tool that enables students to make informed decisions about their future," says Dr. Geneviève Moineau, President and CEO of the AFMC.
Easier than ever before, CANPREPP's website is user friendly and gives medical learners the ability to browse and sort through programs and events. The national web calendar of events is a centralized calendar of events that lets learners learn more about residency programs across the country. Learners can search the calendar by event type, specialty, or school. Programs will update the calendar as the events become available.
About The Association of Faculties of Medicine of Canada (AFMC) Founded in 1943, the Association of Faculties of Medicine of Canada (AFMC) represents Canada's 17 faculties of medicine and is the voice of academic medicine in this country. AFMC's member faculties graduate over 2,700 MDs per year; teach over 11,500 undergraduate medical students; train over 15,000 postgraduate trainees; employ nearly 48,000 full and part-time faculty members and undertake over 3 billion dollars of biomedical and health care research annually. Go to afmc.ca to learn more. Follow AFMC on Twitter, LinkedIn,YouTube.
SOURCE Association of Faculties of Medicine of Canada (AFMC)
Orillia Soldiers' Memorial Hospital Implements Novari Health Surgical Wait List Management System
KINGSTON, ON, Nov. 2, 2021 /CNW/ - Novari Health is pleased to announce it has completed another successful implementation of its surgical wait list management and eBooking technology. Orillia Soldiers' Memorial Hospital is the latest Canadian hospital to implement Novari's surgical access to care technology.
The Novari ATC software has gone live at Orillia Soldiers' Memorial Hospital. The technology is being provided as software as a service (SaaS) to the hospital and all surgical offices. The system provides surgeons and their office staff access to a standardized electronic wait list management system and the ability to electronically coordinate the scheduling of surgeries and procedures with the hospital. The software enhances the ability for collaboration and management of pooled lists of patients waiting for surgery as well as supporting a regional view of the demand for surgical services.
The Ontario Ministry of Health, Ontario Health, and hospitals across the province have been working to mitigate the impact of the COVID-19 pandemic on patients waiting for surgery. Having a modern wait list management system complements these efforts for all patients including those waiting for surgical and medical consults, surgery, and other procedures.
Novari Health's innovative and unique access to care technologies are live and being implemented at dozens of hospitals and regional health authorities across Canada.
"I am thankful for the support from the Ministry of Health and Ontario Health in bringing this exciting innovation to OSMH. Modernizing our surgical scheduling services with Novari ATC will enable OSMH to continue our commitment of improving access to surgical services and reducing wait times. I want to recognize our staff and local surgeons for their outstanding effort and collaboration throughout this project and thank Novari for their partnership." - Tom Roberts, VP-Corporate Services, Chief Financial Officer, Orillia Soldiers' Memorial Hospital
"Having a modern wait list management system in place is an essential tool to help improve wait times for surgery that were worsened by the COVID-19 pandemic. My family has experienced high quality and compassionate care as surgical patients in Orillia, so I couldn't be prouder to now provide their surgical team with our access to care technologies." - John Sinclair, CPHIMS-CA, President, Novari Health
About Novari Health
Novari Health designs, builds, and implements award-winning enterprise scale SaaS solutions that improve access to care, coordination of care, and the delivery of healthcare services. Based in Kingston Ontario and with offices in Vancouver, Australia, and New Zealand, Novari has become one of the largest Canadian based digital health solution providers. ISO 27001 certified, Novari Health is a Microsoft Gold Partner, with software solutions hosted on Microsoft Azure Canadian and Australian cloud data centres. For more information, visit novarihealth.com.
SOURCE Novari Health Inc.
Felix Health Becomes the First Canadian Telemedicine Provider to Offer Integrated Digital Mental Health Services
TORONTO, Nov. 2, 2021 /CNW/ - Game-changing telemedicine platform Felix continues to break down stigma and barriers while paving the way forward for Canadians to receive mental health treatment. The Canadian digital healthcare provider is expanding its current mental health offering to include treating and diagnosing anxiety and depression among Canadians from the comfort of their homes.
A recent survey conducted by the Centre for Addiction and Mental Health revealed that 40 percent of Canadians have experienced feelings of anxiety or depression but have never sought medical help. Felix's new digital mental health care experience will allow more Canadians to easily and discreetly access the support they need.
In a world where digital technology and at-home delivery services enable you to get almost anything you want without leaving your couch, the digital mental health space is still quite limited. Felix understands the demand and is dedicated to meeting patients' needs.
Felix's expansion goes beyond prescription renewals and delivery to provide a more integrated healthcare offering. The service will include audio or video visits with a practitioner who provides a diagnosis and treatment, which is then filled, discreetly packaged, and shipped free within 48 hours by an accredited pharmacy. Patients will be eligible for auto-refills to ensure they always have their medication when they need it, which is an ongoing issue for mental health care.
"When initially launching our mental health services, we felt it was our duty to make treatment more accessible. Refilling pre-prescribed medication was the first step, but we wanted to be able to provide more," said Kyle Zien, CEO and Co-Founder of Felix. "Our initial mental health offering was one of our biggest launches to date, and we are proud to expand our services to provide Canadians even more access and control of their mental health needs in a way that is simple, secure and cost-effective."
Felix's mental health diagnoses will be widely available by the end of October and continue to evolve the offerings over the coming months and years through psychotherapy and more. Felix aims to make healthcare more accessible for Canadians and offers healthcare and treatments for other stigmatized issues such as erectile dysfunction, birth control, hair loss, acne, allergies, cold sores/herpes, migraines, and more. For more information, or have a prescription filled, visit felixforyou.ca.
About Felix
Founded in 2019, Felix is a patient-driven digital healthcare company empowering people to take control of their health and wellbeing. We're passionate about building technology and beautiful product experiences to make healthcare more accessible (and maybe even more enjoyable) for all Canadians. Felix is one of Canada's leading end-to-end healthcare platforms, providing online diagnoses, prescription delivery, and ongoing care for birth control, erectile dysfunction, acne, hair loss, herpes, and more. www.felixforyou.ca
SOURCE Felix
Health Canada issues Notice of Compliance (NOC) for Jardiance® (empagliflozin) for the treatment of heart failure with reduced ejection fraction
This new indication is based on the EMPEROR-Reduced trial, which showed a significant 25 per cent reduction in the combined relative risk versus placebo of cardiovascular death or hospitalization for heart failure with reduced ejection fraction (HFrEF) in adults with or without diabetes and an eGFR as low as 20ml/min/1.73 m21
Heart failure affects nearly 670,000 people in Canada, with close to 93,000 new cases diagnosed each year2
Jardiance was first granted marketing authorization in August 2015 by Health Canada for the treatment of adults with insufficiently controlled type 2 diabetes mellitus3
BURLINGTON, ON and TORONTO, Nov. 2, 2021 /CNW/ - Boehringer Ingelheim (Canada) Ltd and Eli Lilly Canada Inc. are pleased to announce that Jardiance® (empagliflozin) has been granted marketing authorization by Health Canada as a treatment for heart failure with reduced ejection fraction (HFrEF), as an adjunct to standard of care therapy, in adults with an eGFR as low as 20 mL/min/1.73 m2.3The extension of the indication follows marketing authorization granted by Health Canada in 2015 for the treatment of adults with insufficiently controlled type 2 diabetes mellitus; and in 2016, as an add-on combination to reduce the incidence of cardiovascular death in patients with type 2 diabetes mellitus and established cardiovascular disease.3
"When we look at healthcare expenditures for heart failure in Canada, it is hospitalization that makes up the bulk of the attributable expenses for care. With empagliflozin now approved by Health Canada for heart failure with reduced ejection fraction, we can look forward to reducing the risk of hospitalization," says Dr. Shelley Zieroth, Cardiologist and Director at Winnipeg's St. Boniface Hospital Heart Failure and Transplant Clinics and Professor in the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba. "The availability of a new heart failure treatment is a major step forward in improving the standard of care for heart failure patients and is definitely worth celebrating."
The marketing authorization is based on results from the EMPEROR-Reduced trial in which empagliflozin showed a significant 25 per cent reduction in the combined relative risk versus placebo of cardiovascular death or hospitalization due to heart failure.1 The findings from the primary endpoint were consistent in subgroups with or without type 2 diabetes. Key secondary endpoints were also significantly improved with empagliflozin, including a 30 per cent reduction in the relative risk of first and recurrent hospitalization for heart failure.1
Heart failure affects more than 60 million people worldwide.4 In Canada, nearly 670,000 Canadians are currently living with heart failure and close to 93,000 new cases are diagnosed each year.2
"Jardiance was the first SGLT2 inhibitor to demonstrate cardiovascular protective effects and improve cardiovascular outcomes in patients with type 2 diabetes," said Waheed Jamal, M.D., Corporate Vice President and Head of CardioMetabolic Medicine, Boehringer Ingelheim. "We are delighted to now be able to offer Jardiance to people with heart failure with reduced ejection fraction in Canada, regardless of diabetes status."
"The introduction of empagliflozin for this type of heart failure in Canada is a significant milestone for the Boehringer Ingelheim and Lilly Alliance," continued Jeff Emmick, M.D., Ph.D., Vice President, Product Development, Lilly. "We are committed to finding solutions for the millions of people who live with heart failure and important metabolic conditions around the world."
Heart failure is frequently associated with other diseases of the cardio-renal-metabolic systems such as type 2 diabetes and kidney disease. Due to the interconnected nature of these systems, improvement in one system can lead to positive effects throughout the others. Heart failure is a condition in which the heart cannot pump sufficient blood to the rest of the body.5 There are two forms of the condition; heart failure with reduced ejection fraction (HFrEF) means the heart cannot contract normally, while preserved ejection fraction means the heart cannot properly fill with blood. People with heart failure often experience breathlessness and fatigue, which can severely impact their quality of life.6,7
The EMPEROR-Reduced trial is part of the EMPOWER clinical program, the broadest and most comprehensive of any SGLT2 inhibitor, exploring the impact of empagliflozin on the lives of people across the spectrum of cardio-renal-metabolic conditions.
About the EMPEROR Heart Failure Studies8,9 The EMPEROR (EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure) heart failure studies are two Phase III, randomized, double-blind trials investigating once-daily empagliflozin compared with placebo in adults with heart failure with preserved or reduced ejection fraction, with or without diabetes, who are receiving current standard of care:
EMPEROR-Reduced [NCT03057977] investigated the safety and efficacy of empagliflozin in patients with chronic heart failure with reduced ejection fraction (HFrEF).
Primary endpoint: time to first event of adjudicated cardiovascular death or adjudicated hospitalization for heart failure
Number of patients: 3,730, which included 36 study sites in Canada
Completion: 2020
EMPEROR-Preserved[NCT03057951] investigated the safety and efficacy of empagliflozin in patients with chronic heart failure with preserved ejection fraction (HFpEF).
Primary endpoint: time to first event of adjudicated cardiovascular death or adjudicated hospitalization for heart failure
Number of patients: 5,988, which included 34 study sites in Canada
Completion: 2021
About the EMPOWER Program The Alliance has developed the EMPOWER program to explore the impact of empagliflozin on major clinical cardiovascular and renal outcomes in a spectrum of cardio-renal-metabolic conditions. Cardio-renal-metabolic conditions are the leading cause of mortality worldwide and account for up to 20 million deaths annually.10 Through the EMPOWER program, Boehringer Ingelheim and Lilly are working to advance knowledge of these interconnected systems and create care which offers integrated, multi-organ benefits. Comprised of eight clinical trials and two real-world evidence studies, EMPOWER reinforces the long-term commitment of the Alliance to improve outcomes for people living with cardio-renal-metabolic conditions. With more than 400,000 adults studied worldwide in clinical studies, it is the broadest and most comprehensive clinical program for an SGLT2 inhibitor to date.
About heart failure Heart failure is a serious condition, that occurs when the heart cannot keep up with its workload, and the body may not get the oxygen that it needs. As the left and right sides of the heart fail, fluid may build up in the lungs, abdomen, or legs.5,11 It is a common condition affecting over 60 million people worldwide and expected to increase as the population ages.4,12 In Canada, nearly 670,000 people are living with heart failure.2Heart failure is twice as common in people with diabetes.13
There are different types of heart failure. People with left-sided heart failure have either a reduced or a preserved ejection fraction. Ejection fraction is a measurement of the percentage of blood the left ventricle pumps out with each contraction.14 When the heart relaxes, the ventricle refills with blood.
Heart failure with preserved ejection fraction occurs when the left ventricle of the heart is unable to relax and properly fill with blood, resulting in less blood being available to be pumped out to the body.14
Heart failure with reduced ejection fraction occurs when the left ventricle of the heart is not able to contract effectively, which means that the heart cannot pump with enough force, so less blood is pushed out to the body.14
People with heart failure often experience shortness of breath and fatigue, which can severely impact their quality of life.7 Individuals with heart failure often also have impaired kidney function, which can further worsen patient outcomes and quality of life.15
About cardio-renal-metabolic conditions Boehringer Ingelheim and Lilly are driven to transform care for people with cardio-renal-metabolic conditions, a group of interconnected disorders that affect more than one billion people worldwide and are a leading cause of death.4,10
Through our research and treatments, our goal is to support people's health, restoring the balance between the interconnected cardio-renal-metabolic systems and reducing their risk of serious complications. As part of our commitment to those whose health is jeopardized by cardio-renal-metabolic conditions, we will continue embracing a multidisciplinary approach towards care and focusing our resources on filling treatment gaps.
About empagliflozin Empagliflozin (marketed as Jardiance®) is an oral, once-daily, highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor. It was the first type 2 diabetes medicine to include in its label in several countries cardiovascular death risk reduction data in patients with type 2 diabetes and established cardiovascular disease.16,17,18,3
Empagliflozin is currently indicated for the treatment of adults with insufficiently controlled type 2 diabetes and as an adjunct to diet, exercise and standard care therapy to reduce the incidence of cardiovascular death in patients with type 2 diabetes mellitus and established cardiovascular disease.16,17,18,3 Additionally, empagliflozin is approved for the treatment of adults with HFrEF in the European Union and the U.S.16,19 Boehringer Ingelheim and Lilly Alliance plan for global regulatory submissions in HFpEF in 2021. Research is ongoing regarding the effects of empagliflozin on hospitalization for heart failure and mortality in post-myocardial infarction (heart attack) patients with high risk of heart failure.20 Empagliflozin is also currently being investigated in chronic kidney disease.21
Boehringer Ingelheim and Eli Lilly and Company In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an Alliance that centers on compounds representing several of the largest diabetes treatment classes. Depending on geographies, the companies either co-promote or separately promote the respective molecules each contributing to the Alliance. The Alliance leverages the strengths of two of the world's leading pharmaceutical companies to focus on patient needs. By joining forces, the companies demonstrate their commitment, not only to the care of people with diabetes, but also to investigating the potential to address areas of unmet medical need. Clinical trials have been initiated to evaluate the impact of empagliflozin on people living with heart failure or chronic kidney disease.
About Boehringer Ingelheim (Canada) Ltd. Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Approximately 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing. The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs approximately 600 people across Canada. Learn more at www.boehringer-ingelheim.ca.
About Eli Lilly Canada Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by Colonel Eli Lilly, who was committed to creating high quality medicines that meet people's needs, and today we remain true to that mission in all our work. Lilly employees work to discover and bring life-changing medicines to people who need them, improve the understanding and management of disease, and contribute to our communities through philanthropy and volunteerism.
Eli Lilly Canada was established in 1938, the result of a research collaboration with scientists at the University of Toronto, which eventually produced the world's first commercially available insulin. Our work focuses on oncology, diabetes, autoimmunity, neurodegeneration, and pain. To learn more about Lilly Canada, please visit us at www.lilly.ca.
For our perspective on issues in healthcare and innovation, follow us on Twitter @LillyPadCA and @LillyMedicalCA.
References ______________________________
1
Packer M, Anker SD, Butler J, et al. Cardiac and Renal Outcomes With Empagliflozin in Heart Failure With a Reduced Ejection Fraction. N Engl J Med. 2020;383:1413–24.
Jardiance Product Monograph. Boehringer Ingelheim (Canada) Ltd. October 29, 2021
4
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858.
Calvert MJ, Freemantle N, Cleland JGF. The impact of chronic heart failure on health–related quality of life data acquired in the baseline phase of the CARE–HF study. Eur J Heart Fail. 2005;7(2):243–51.
GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. The Lancet. 2016; 388(10053):1459–544.
Together by St. Jude Teaches Children about the COVID-19 Vaccines in New Coloring BookFollowing FDA emergency use approval of the COVID-19 vaccine for 5- to 11-year-olds, Together by St. Jude releases a free coloring book that educates children on COVID-19 vaccinesMEMPHIS, TENN – Experts at St. Jude Children’s Research Hospital have created a coloring book to help children learn about vaccines and how they work to prevent COVID-19. The coloring book comes on the heels of the US Food and Drug Administration’s emergency use approval of the COVID-19 vaccine for children ages 5-11. Developed and reviewed by patient education and infectious disease specialists at St. Jude, the coloring book is available for download on the Together by St. Jude web-based resource. A St. Jude Coloring Book: COVID-19 Vaccines answers questions about COVID-19 vaccines in words children can understand. “A COVID-19 vaccine uses the body’s immune system to fight the coronavirus,” the book reads. “Your immune system is like a team of superheroes that protect you from germs.” The book also uses simple pictures to show how the vaccine works to help your body make antibodies to fight the virus that causes COVID-19. “The vaccine coloring book offers children the opportunity to learn more about the COVID-19 vaccine by coloring images of doctors, children and the COVID-19 virus,” said Rachel Schmelzer, a child life specialist at St. Jude. “The illustrations in the book help to prepare children for the vaccination process and explain how the vaccine works to protect their bodies from COVID-19.”
Free Online Coloring Books: A St. Jude Initiative for Patient Education and Care Together by St. Jude published its first coloring book on COVID-19 in 2020. Learn About the Coronavirus helped children understand the virus and taught ways to stay healthy by keeping a distance, wearing a mask, and washing hands often. That coloring book was translated into 16 different languages and was downloaded over 14,000 times in more than 150 countries and territories. “Throughout the pandemic, parents have struggled through numerous difficult conversations with their children. We want to prepare our children for the significant changes in their daily lives and teach them how to stay safe, but how can we do this without scaring them?” said Niki Jurbergs, PhD, St. Jude Psychology Department. “We created these coloring books to prepare parents with the tools they need to introduce these new and potentially scary concepts in an age-appropriate way. Having a plan ahead of time, including talking points, can make parents feel more comfortable during this conversation.” The coloring books are an example of how Together by St. Jude supports the hospital in setting the standard for pediatric cancer care and patient experience. St. Jude staff collaborated with infectious diseases specialists to create accurate but accessible and interactive educational material to meet the needs of families affected by pediatric cancer. The coloring books have value for parents and children everywhere, not just St. Jude patients. In addition to the two COVID-19 coloring books, Together by St. Jude has also released Riley Takes Medicine, a coloring book that teaches children undergoing cancer treatment about the different types of drugs and the importance of medication compliance. All three coloring books are available for free to download. To speak with the specialists at St. Jude, please contact Katy Hobgood Ray at Katy.Hobgood@STJUDE.ORG or 901-568-9869 About Together by St. JudeTogether by St. Judeis a comprehensive online resource dedicated to pediatric cancer patients and their families. It provides trustworthy, up-to-date medical information and connects families facing pediatric cancer with personally relevant topics in a clear, easy to use format. Together by St. Jude focuses on providing content that appeals to a variety of preferred learning styles and offers resources that families can use throughout the entire cancer journey. Content have been translated into 8 different languages. Like Together on Facebook.
# # # St. Jude Children’s Research Hospital St. Jude Children’s Research Hospital is leading the way the world understands, treats, and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20% to 80% since the hospital opened more than 50 years ago. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing, and food—because all a family should worry about is helping their child live. To learn more, visit stjude.org or follow St. Jude on social media at @stjuderesearch.
Collaboration between Medfuture and Nautilus Plus - Medfuture and Nautilus Plus join forces to create the Vivre Plus Solution
MIRABEL, QC, Nov. 2, 2021 /CNW Telbec/ - Medfuture and Nautilus Plus are announcing today that they have joined forces to offer the Vivre Plus Solution to the Quebec population. Combining the offerings of the two companies that share a common mission to promote wellness, the Vivre Plus Solution offers an innovative approach by bringing together the expertise of Nautilus Plus' kinesiologists and nutritionists with that of Medfuture's health professionals. In doing so, the Vivre Plus Solution offers 360˚ support to improve the quality of life of Nautilus Plus members so they can live better and longer lives.
A collaboration for a unique offer in Quebec
The primary objective of this collaboration is to offer a personalized and multidisciplinary approach to better guide the recommendations of health professionals while identifying ways to apply them directly to the daily lives of Nautilus Plus members.
Whether it's through the creation of a personalized action plan or through daily follow-up to prevent health problems, Medfuture and Nautilus Plus have developed a unique approach in Quebec, aimed at improving the quality of life of Nautilus Plus members by supporting them in the many areas of their health.
To meet the needs of the Quebec population
This solution is for all those :
Who wish to better control their particular conditions such as diabetes, cardiovascular problems, arthritis, osteoarthritis or others;
Who wish to relieve small physical ailments that have developed over the years;
Who are preparing for their retirement or are already there and want to make the most of it;
Who want to know more about their current overall health status with physical, physiological and cognitive assessments.
The services in the Vivre Plus solution offer different benefits, depending on the clientele and the type of package chosen:
Complete physical health assessment performed by the kinesiologist;
Nutritional consultation performed by the nutritionist;
Vitality Index Analysis;
Requisition for blood works if needed;
Clinical vidéo consultation;
Access to Nautilus Plus facilities for 8 weeks;
Adapted training program and follow-up sessions by the kinesiologist;
Nutritional plan and follow-up sessions by the nutritionist;
Quotes "Medfuture is proud of this promising collaboration, which perfectly reflects our mission to promote the well-being of our clientele. Nautilus Plus shares our mission and promotes a preventive approach to health for the Quebec population. The result of our collaboration is a unique offer in Quebec, the Vivre Plus solution, which puts forth a multidisciplinary support to meet the needs of people who want to live better and longer."
- Amélie Paquette,Medfuture's General Manager
"At Nautilus Plus, we search for partners committed to a global health approach. This is the primary reason behind the development of the Vivre Plus solution with Medfuture, a Quebec company that takes the health of its population to heart and places the patient and his or her well-being at the center of its approach. Nautilus Plus recognizes itself in the human and positive values of Medfuture. We listen to our members and support them in achieving their goals. The Vivre Plus solution offers winning conditions for our clients."
– Martin Légaré, Chief Executive Officer, Nautilus Plus
About Medfuture Clinic Inc. Medfuture specializes in the longevity field by helping people who actively seek control over their health, their most precious possession, to live an optimal and long life. Medfuture is a facilitator that aims to slow, stop or reverse the consequences of aging using tools to measure biomarkers related to the processes involved and concrete preventive actions, all with the use of advanced technologies and the practice of personalized medicine. Medfuture's multidisciplinary team offers a unique, human-centered experience.
About Nautilus Plus Nautilus Plus is dedicated to improving the health of the Quebec population. It offers its members optimal conditions to improve their health and quality of life by practicing regular physical fitness and adopting a healthy diet. Nautilus Plus' mission is to actively participate in the well-being of the population. Nautilus Plus' promise is to offer more: to provide optimal conditions for better training with the best specialists, the best programs and the best equipment.
Curtain Pulled Back on ‘Alarming’ Health Care Practices
Concord, NC, Nov. 2, 2021 — After 28 years in the health care business, Dr. David Wilcox has seen enough to realize that it truly is a “business,” as opposed to the kind-hearted healing service that most of us might imagine it to be. His new book reveals some unsettling facts.
“There is little to no transparency about procedures or billing,” Dr. Wilcox says, “and the average health care consumer doesn't think about it until they have to access the healthcare system. That is a dangerous mentality, as we all will need health care at some point in our lives.”
In his book, How to Avoid Being a Victim of the American Healthcare System: A Patient’s Handbook for Survival, Dr. Wilcox offers information, facts and tips that can help patients and family members navigate through the morass.
“I have seen some alarming situations that nursing school never prepared me for,” Dr. Wilcox said. “Not being prepared and knowledgeable means you will have little control over the health care you receive.”
His goal in writing this book was to level the playing field, enabling consumers of health care to understand how to avoid getting caught in the systemic net.
In his own words, Dr. Wilcox’s book explores “what to do if you have to go to a hospital, how to handle an insurance company’s claim denial, how to find an alternative to high-priced prescriptions and why the current pay-for-fee system is inadequate. You will also discover the direction the healthcare system needs to move in, to holistically care for you, the patient … information that the health care entities would prefer you didn’t know.”
Dr. David Wilcox is a health care professional who believes proactive patient education enables those accessing the healthcare system to be better partners in their health care. He also believes that everyone has the right to access the American Healthcare System safely. A Doctorate-prepared nurse who also holds a Master’s in Health Administration and is Board Certified in Nursing Informatics, Dr. Wilcox has nearly three decades of health care experience as a bedside nurse, hospital administrator and in health care information technology, which has helped him to develop his unique perspective on the American Healthcare System. For more information, please visit https://drdavidwilcox.com/.
How to Avoid Being a Victim of the American Healthcare System: A Patient’s Handbook for Survival
